Trial Profile

A Phase 1, First-in-Human Study of NTX-1088, a Monoclonal Antibody Targeting the Poliovirus Receptor (PVR, CD155), as Monotherapy and Combined With Pembrolizumab, in Patients With Advanced Solid Malignancies

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 11 Aug 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

29 Jul 2025 Planned End Date changed from 1 Dec 2025 to 1 Dec 2026.
29 Jul 2025 Planned primary completion date changed from 1 Jun 2025 to 1 Dec 2025.
06 May 2024 According to Nectin Therapeutics media release, Guangzhou-Israel Biotechnology Fund (GIBF) invested in Nectin Therapeutics to continue the development of Nectin's portfolio of novel immuno-oncology products and this global phase I trial.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com